SOURCE: AtheroGenics

August 03, 2006 14:46 ET

AtheroGenics to Present at 26th Annual Canaccord Adams Summer Seminar on August 10, 2006

ATLANTA, GA -- (MARKET WIRE) -- August 3, 2006 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present a company overview and update at the 26th Annual Canaccord Adams Summer Seminar on Thursday, August 10, 2006, at 8:00 a.m. EDT at The Boston Marriott Long Wharf in Boston, Massachusetts.

A live audio webcast of the presentation will be available on the Company's Investor Relations website at http://www.atherogenics.com/investor/stock.html. A replay of the presentation will be available on the AtheroGenics website for 30 days.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit www.atherogenics.com.

Contact Information

  • CONTACTS:
    Corporate Communications
    Donna L. Glasky
    AtheroGenics, Inc.
    678-336-2517
    Email Contact

    Media Inquiries
    Jayme Maniatis
    Schwartz Communications, Inc.
    781-684-0770
    Email Contact

    Investor Inquiries
    Lilian Stern
    Stern Investor Relations, Inc.
    212-362-1200
    Email Contact